Stack Creep

Stack Creep is the gradual expansion of a supplement routine until the routine itself becomes the intervention, even when the evidence, endpoints, and owners are unclear.

Also known as: supplement sprawl, protocol drift, pill-stack bloat, supplement accretion

Stack Creep starts with one defensible bottle: a low vitamin D result, a training block, a sleep problem, or a clinician’s recommendation. It fails when later bottles survive because they once sounded plausible.

Context

Longevity nutrition invites accumulation. A capsule can be justified because it touches AMPK, mTOR, NAD+, inflammation, methylation, glucose, sleep, or mitochondrial function. The failure is the missing review.

Over time, a person can move from a multivitamin and vitamin D to 15, 25, or 40 products. Bryan Johnson’s roughly 100-pill Blueprint-style stack is the limit case. Ordinary versions are quieter: subscriptions, half-used bottles, overlapping powders, no written reason each item remains.

Clinician-directed supplementation for iron deficiency, vitamin B12 deficiency, vitamin D deficiency, pregnancy-related folate needs, malabsorption, post-bariatric surgery supplementation, and diagnosed medical conditions can be ordinary.

Problem

Each supplement is easier to justify alone than the stack is to defend a year later. The evidence is assessed item by item: a small trial, a plausible mechanism, an observational association, an expert protocol, or a biomarker story. The combined system is rarely tested.

Risk and cost compound quietly. Ten items can overlap in dose, affect medications, complicate surgery planning, alter lab interpretation, raise bleeding risk, irritate the gastrointestinal tract, or hide what caused a symptom. A $25 bottle can become a $200 to $800 monthly habit.

The deeper failure is borrowed judgment. Without a rationale, dose, endpoint, and stopping rule, the copied protocol becomes belief with inventory.

Forces

• Mechanism language makes weak claims feel precise.
• Adding feels active; subtracting feels like losing protection.
• Small item costs hide the stack cost.
• Supplement regulation leaves unusual responsibility on the buyer.
• A product can be useful for a documented indication and unjustified as a permanent longevity default.
• Personality protocols reward visible complexity, not measurement discipline.
• Clinicians can miss interaction risks when patients do not disclose the full list.

Solution

Replace stack logic with an item-by-item ledger and a subtraction review. Every item answers the same questions: Indication (deficiency, clinician support, dietary gap, symptom target, or speculative longevity rationale); Evidence tier (strongest evidence for the claim, using Evidence Tiers); Dose; Interaction risk; Cost; Measurable endpoint; Stopping rule; and Owner.

A supplement can stay because it corrects a deficiency, supports a clinician-directed plan, has a clean endpoint, or carries low cost and low interaction risk for a bounded experiment. It should not stay because “it might help” was once plausible.

The audit borrows from medication review without treating supplements as prescription drugs. Periodically, every item re-earns its place. Duplicates, expired experiments, normalized lab responses, and ownerless add-ons surface.

Basic nutrition gets priority. Mediterranean Diet Pattern, Protein Intake for Sarcopenia Prevention, and food-level Polyphenol Intake often answer stronger questions than another capsule. A stack that grows while diet quality, protein, training, sleep, and medication disclosure remain thin is poorly governed.

Evidence

Evidence tier: Observational (human, large) for supplement prevalence and adverse-event surveillance; mixed evidence by individual supplement and endpoint. Stack Creep is a failure mode, not a diagnosis.

Kantor and colleagues analyzed National Health and Nutrition Examination Survey data from 1999 to 2012. About 52% of US adults reported using at least one supplement in the prior 30 days in both the 1999-2000 and 2011-2012 cycles. The mix changed: multivitamin and multimineral use fell, vitamin D and fish oil rose (Kantor et al., 2016).

The preventive-outcome evidence is thinner than the market implies. In 2022, the US Preventive Services Task Force found insufficient evidence for multivitamins and most single or paired nutrients for primary prevention of cardiovascular disease or cancer in community-dwelling, nonpregnant adults, and recommended against beta carotene and vitamin E (USPSTF, 2022).

Regulation makes that concern practical. The FDA does not approve dietary supplements for safety or effectiveness before marketing. The FTC requires competent and reliable scientific evidence for health-related advertising claims. The NIH Office of Dietary Supplements advises keeping a complete list and sharing it with clinicians.

Safety signals are not hypothetical. Geller and colleagues used a nationally representative sample of 63 emergency departments from 2004 to 2013 and estimated about 23,000 US emergency department visits per year, with about 2,000 hospitalizations, related to dietary supplement adverse events. Many involved weight-loss and energy products; in adults aged 65 and older, micronutrient-pill swallowing problems were notable (Geller et al., 2015).

How It Plays Out

A 48-year-old starts vitamin D after a low lab value. Then come magnesium for sleep, fish oil for cardiovascular risk, creatine for training, curcumin for inflammation, berberine after a glucose thread, glycine after a podcast, collagen for joints, and a mixed “mitochondrial” product. A year later, vitamin D may still be defensible. The stack around it is not clearly owned.

A 67-year-old brings a medication list to a primary-care visit but omits supplements because they do not feel like medicines. The clinician sees an anticoagulant, upcoming dental surgery, and normal liver enzymes, but not the high-dose fish oil, garlic extract, turmeric blend, sleep product, and green-tea extract. Care now rests on an incomplete list.

A performance-focused reader uses a biological-age test every quarter and adds a new supplement whenever the score disappoints. The inputs are too many to interpret: sleep, training load, weight loss, inflammation, lab variability, supplement timing, or the test itself. Biological Age is a poor owner for an unstructured stack.

The Bryan Johnson-style protocol is unusually documented, measured, and resourced. That makes it interesting as a self-experiment. It does not make the pill count transferable. Copying the visible stack without the measurement system, clinical review, adverse-event tracking, and willingness to revise turns a public protocol into Lifestyle Theater.

Consequences

Benefits. Naming Stack Creep keeps per-supplement discussion from reading as endorsement. A reader can learn about creatine, vitamin D, omega-3s, magnesium, polyphenols, or NAD-adjacent compounds without converting every plausible item into a permanent purchase.

The audit also recovers money, attention, and clinical clarity. A $300 monthly stack is not automatically wasteful, but it competes with food quality, resistance training, sleep support, dental care, blood-pressure management, ApoB follow-up, coaching, and time. A complete list can change how a clinician reads bleeding risk, liver enzymes, kidney function, palpitations, gastrointestinal symptoms, sleepiness, surgery planning, pregnancy or nursing, and drug interactions.

Liabilities. The correction can slide into supplement nihilism. Supplements have clear roles in documented deficiency, pregnancy-related folate needs, diagnosed conditions, restricted diets, malabsorption, older-adult nutrition, sports nutrition, and clinician-directed care. The antipattern is accumulation without governance, not supplementation itself.

The ledger can create false precision. It does not prove efficacy; it makes the decision legible enough to review. Some endpoints are subjective, some trials are short, and some risks are unknown until wide use. The right posture is disciplined uncertainty: fewer permanent assumptions, explicit ownership, and no shame in removing what no longer has a job.

Related Articles

Sources

• Kantor, Elizabeth D., Colin D. Rehm, Mengmeng Du, Emily White, and Edward L. Giovannucci. “Trends in Dietary Supplement Use Among US Adults From 1999-2012.” JAMA 316, no. 14 (2016): 1464-1474.
• Geller, Andrew I., Nadine Shehab, Neal J. Weidle, Mary C. Lovegrove, Benjamin J. Wolpert, Babgaleh B. Timbo, et al. “Emergency Department Visits for Adverse Events Related to Dietary Supplements.” New England Journal of Medicine 373 (2015): 1531-1540.
• US Preventive Services Task Force. “Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA 327, no. 23 (2022): 2326-2333.
• US Food and Drug Administration. “Questions and Answers on Dietary Supplements.” Content current as of February 21, 2024.
• NIH Office of Dietary Supplements. “Dietary Supplements: What You Need to Know.” Updated January 4, 2023.
• Federal Trade Commission. “Health Products Compliance Guidance.” December 2022.
• Hung, Anna, Yoon Hie Kim, and Juliessa M. Pavon. “Deprescribing in Older Adults with Polypharmacy.” BMJ 385 (2024): e074892.

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

Supplement decisions that intersect with prescription medications, diagnosed conditions, pregnancy, nursing, surgery, anticoagulant or antiplatelet therapy, liver disease, kidney disease, cancer treatment, eating-disorder history, frailty, unexplained weight loss, or a documented deficiency require qualified clinical supervision. Clinician-directed supplementation for a measured deficiency or indication is different from Stack Creep.